Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SUSAN PERLMAN

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1114945474
CMS profile
5050
Location
LOS ANGELES, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$2,525.00

3 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $2,525.00 3

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
PTC Therapeutics, Inc. $2,000.00 1
Vertex Pharmaceuticals Incorporated $525.00 2

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SUSAN PERLMAN

NPI 1114945474 · CMS profile ID 5050

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

LOS ANGELES, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1114945474?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SUSAN PERLMAN, NPI 1114945474, CMS profile ID 5050. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1114945474?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). SUSAN PERLMAN, NPI 1114945474, CMS profile ID 5050. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1114945474?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
SUSAN PERLMAN, NPI 1114945474, CMS profile ID 5050, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1114945474?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

3 matching records · $2,525.00 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 3 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–3 of 3.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PTC Therapeutics, Inc. $2,000.0010/29/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848935359 CMS
Vertex Pharmaceuticals Incorporated $180.8305/24/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 786506563 CMS
Vertex Pharmaceuticals Incorporated $344.1704/29/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 786507271 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2020 $0.83 1
PY2021 $2,525.00 3
PY2022 $9.49 4
PY2023 $3,528.29 4
PY2024 $23,648.66 8
PY2025 $40,950.09 19

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $301,584.35 26
PY2024 Principal investigator $407,420.40 21
PY2023 Principal investigator $362,150.52 25
PY2022 Principal investigator $539,606.64 35
PY2021 Recipient $2,260.00 1
PY2021 Principal investigator $371,997.54 34
PY2020 Principal investigator $21,712.10 3
PY2019 Principal investigator $96,388.80 8

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

35 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $5,040.00 12/16/2022 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Randomized Double-Blind Placebo-Controlled Parallel- Group Study to Evaluate the Efficacy and Safety of BHV-3241 in Subjects With Multiple System Atrophy (M-STAR Study) No dispute reported 06/30/2026 933375389
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $78,019.20 12/16/2022 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Randomized Double-Blind Placebo-Controlled Parallel- Group Study to Evaluate the Efficacy and Safety of BHV-3241 in Subjects With Multiple System Atrophy (M-STAR Study) No dispute reported 06/30/2026 933375395
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $27,216.00 12/16/2022 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Randomized Double-Blind Placebo-Controlled Parallel- Group Study to Evaluate the Efficacy and Safety of BHV-3241 in Subjects With Multiple System Atrophy (M-STAR Study) No dispute reported 06/30/2026 933375403
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $7,245.00 12/16/2022 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Randomized Double-Blind Placebo-Controlled Parallel- Group Study to Evaluate the Efficacy and Safety of BHV-3241 in Subjects With Multiple System Atrophy (M-STAR Study) No dispute reported 06/30/2026 933375411
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $1,260.00 12/16/2022 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Randomized Double-Blind Placebo-Controlled Parallel- Group Study to Evaluate the Efficacy and Safety of BHV-3241 in Subjects With Multiple System Atrophy (M-STAR Study) No dispute reported 06/30/2026 933375419
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $8,986.32 12/16/2022 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Randomized Double-Blind Placebo-Controlled Parallel- Group Study to Evaluate the Efficacy and Safety of BHV-3241 in Subjects With Multiple System Atrophy (M-STAR Study) No dispute reported 06/30/2026 933375427
Principal investigator 1 PTC Therapeutics, Inc. $20,835.51 12/06/2022 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A RANDOMIZED, PARALLEL-ARM, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY WITH OPEN-LABEL EXTENSION TO ASSESS THE EFFICACY AND SAFETY OF VATIQUINONE FOR THE TREATMENT OF FRIEDREICH ATAXIA (MOVE-FA) No dispute reported 06/30/2026 960190931
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $54,759.30 11/03/2022 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Randomized Double-Blind Placebo-Controlled Parallel- Group Study to Evaluate the Efficacy and Safety of BHV-3241 in Subjects With Multiple System Atrophy (M-STAR Study) No dispute reported 06/30/2026 933375381
Principal investigator 1 PTC Therapeutics, Inc. $18,906.06 11/03/2022 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A RANDOMIZED, PARALLEL-ARM, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY WITH OPEN-LABEL EXTENSION TO ASSESS THE EFFICACY AND SAFETY OF VATIQUINONE FOR THE TREATMENT OF FRIEDREICH ATAXIA (MOVE-FA) No dispute reported 06/30/2026 960190911
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $3,572.10 10/20/2022 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Randomized Double-Blind Placebo-Controlled Parallel- Group Study to Evaluate the Efficacy and Safety of BHV-3241 in Subjects With Multiple System Atrophy (M-STAR Study) No dispute reported 06/30/2026 933375373
Principal investigator 1 SANOFI US SERVICES INC. $19,102.36 09/12/2022 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Venglustat in Late-onset GM2 Gangliosidosis (Tay-Sachs Disease and Sandhoff Disease) Together With a Separate Basket for Juvenile/Adolescent Late-onset GM2 Gangliosidosis and Ultra-rare Diseases Within the Same and Similar Glucosylceramide-based Sphingolipid Pathway No dispute reported 06/30/2026 935665459
Principal investigator 1 SANOFI US SERVICES INC. $3,452.84 09/12/2022 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Venglustat in Late-onset GM2 Gangliosidosis (Tay-Sachs Disease and Sandhoff Disease) Together With a Separate Basket for Juvenile/Adolescent Late-onset GM2 Gangliosidosis and Ultra-rare Diseases Within the Same and Similar Glucosylceramide-based Sphingolipid Pathway No dispute reported 06/30/2026 935665475
Principal investigator 1 SANOFI US SERVICES INC. $56,739.62 09/12/2022 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Venglustat in Late-onset GM2 Gangliosidosis (Tay-Sachs Disease and Sandhoff Disease) Together With a Separate Basket for Juvenile/Adolescent Late-onset GM2 Gangliosidosis and Ultra-rare Diseases Within the Same and Similar Glucosylceramide-based Sphingolipid Pathway No dispute reported 06/30/2026 935665499
Principal investigator 1 PTC Therapeutics, Inc. $24,067.38 09/06/2022 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A RANDOMIZED, PARALLEL-ARM, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY WITH OPEN-LABEL EXTENSION TO ASSESS THE EFFICACY AND SAFETY OF VATIQUINONE FOR THE TREATMENT OF FRIEDREICH ATAXIA (MOVE-FA) No dispute reported 06/30/2026 960190901
Principal investigator 1 Biogen, Inc. $22,653.00 08/05/2022 Non-covered Recipient Entity
The Regents of the University of California Los Angeles
A Phase 1, Blinded, Randomized, Placebo-controlled Study toInvestigate the Safety, Tolerability, and Pharmacokinetics of MultipleAscending Doses of BIIB132 Administered Intrathecally to AdultsWith Spinocerebellar Ataxia 3 No dispute reported 06/30/2026 927058271
Principal investigator 1 PTC Therapeutics, Inc. $17,355.21 08/03/2022 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A RANDOMIZED, PARALLEL-ARM, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY WITH OPEN-LABEL EXTENSION TO ASSESS THE EFFICACY AND SAFETY OF VATIQUINONE FOR THE TREATMENT OF FRIEDREICH ATAXIA (MOVE-FA) No dispute reported 06/30/2026 960190891
Principal investigator 1 PTC Therapeutics, Inc. $10,789.54 07/06/2022 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A RANDOMIZED, PARALLEL-ARM, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY WITH OPEN-LABEL EXTENSION TO ASSESS THE EFFICACY AND SAFETY OF VATIQUINONE FOR THE TREATMENT OF FRIEDREICH ATAXIA (MOVE-FA) No dispute reported 06/30/2026 960190887
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $28,363.94 06/07/2022 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase III Long-Term Randomized Doubleblind Placebo-controlled Trial of Troriluzole in Adult Subjects with Spinocerebellar Ataxia No dispute reported 06/30/2026 933375359
Principal investigator 1 PTC Therapeutics, Inc. $34,528.57 05/04/2022 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A RANDOMIZED, PARALLEL-ARM, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY WITH OPEN-LABEL EXTENSION TO ASSESS THE EFFICACY AND SAFETY OF VATIQUINONE FOR THE TREATMENT OF FRIEDREICH ATAXIA (MOVE-FA) No dispute reported 06/30/2026 960190855
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $22,201.20 05/02/2022 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase IIb/III Randomized Double-blind Placebo-controlled Trial of Troriluzole in Adult Subjects with Spinocerebellar Ataxia No dispute reported 06/30/2026 933375351
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $70.00 05/01/2022 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Randomized Double-Blind Placebo-Controlled Parallel- Group Study to Evaluate the Efficacy and Safety of BHV-3241 in Subjects With Multiple System Atrophy (M-STAR Study) No dispute reported 06/30/2026 933375345
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $1,778.40 04/27/2022 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Randomized Double-Blind Placebo-Controlled Parallel- Group Study to Evaluate the Efficacy and Safety of BHV-3241 in Subjects With Multiple System Atrophy (M-STAR Study) No dispute reported 06/30/2026 933375337
Principal investigator 1 Sage Therapeutics, Inc. $4,800.00 04/07/2022 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
Psychometric Validation Study for the Huntington?s Disease Everyday Functioning (Hi-DEF) Scale No dispute reported 06/30/2026 905449775
Principal investigator 1 PTC Therapeutics, Inc. $526.96 04/05/2022 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A RANDOMIZED, PARALLEL-ARM, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY WITH OPEN-LABEL EXTENSION TO ASSESS THE EFFICACY AND SAFETY OF VATIQUINONE FOR THE TREATMENT OF FRIEDREICH ATAXIA (MOVE-FA) No dispute reported 06/30/2026 960190845
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $70.00 04/01/2022 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Randomized Double-Blind Placebo-Controlled Parallel- Group Study to Evaluate the Efficacy and Safety of BHV-3241 in Subjects With Multiple System Atrophy (M-STAR Study) No dispute reported 06/30/2026 933375329
Principal investigator 1 PTC Therapeutics, Inc. $37,087.71 03/08/2022 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A RANDOMIZED, PARALLEL-ARM, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY WITH OPEN-LABEL EXTENSION TO ASSESS THE EFFICACY AND SAFETY OF VATIQUINONE FOR THE TREATMENT OF FRIEDREICH ATAXIA (MOVE-FA) No dispute reported 06/30/2026 960190835
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $70.00 03/01/2022 Non-covered Recipient Entity
UNIVERSITY OF CALIFORNIA LOS ANGELES
A Randomized Double-Blind Placebo-Controlled Parallel- Group Study to Evaluate the Efficacy and Safety of BHV-3241 in Subjects With Multiple System Atrophy (M-STAR Study) No dispute reported 06/30/2026 933381387
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $3,556.80 02/24/2022 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Randomized Double-Blind Placebo-Controlled Parallel- Group Study to Evaluate the Efficacy and Safety of BHV-3241 in Subjects With Multiple System Atrophy (M-STAR Study) No dispute reported 06/30/2026 933375321
Principal investigator 1 PTC Therapeutics, Inc. $5,307.12 02/07/2022 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A RANDOMIZED, PARALLEL-ARM, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY WITH OPEN-LABEL EXTENSION TO ASSESS THE EFFICACY AND SAFETY OF VATIQUINONE FOR THE TREATMENT OF FRIEDREICH ATAXIA (MOVE-FA) No dispute reported 06/30/2026 960190815
Principal investigator 2 Biohaven Pharmaceutical Holding Company Ltd. $35.00 02/01/2022 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Randomized Double-Blind Placebo-Controlled Parallel- Group Study to Evaluate the Efficacy and Safety of BHV-3241 in Subjects With Multiple System Atrophy (M-STAR Study) No dispute reported 06/30/2026 933375313
Principal investigator 2 Biohaven Pharmaceutical Holding Company Ltd. $35.00 02/01/2022 Non-covered Recipient Entity
MASSACHUSETTS GENERAL HOSPITAL
A Randomized Double-Blind Placebo-Controlled Parallel- Group Study to Evaluate the Efficacy and Safety of BHV-3241 in Subjects With Multiple System Atrophy (M-STAR Study) No dispute reported 06/30/2026 933379071
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $7,090.20 01/25/2022 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Randomized Double-Blind Placebo-Controlled Parallel- Group Study to Evaluate the Efficacy and Safety of BHV-3241 in Subjects With Multiple System Atrophy (M-STAR Study) No dispute reported 06/30/2026 933375305
Principal investigator 1 PTC Therapeutics, Inc. $14,016.30 01/06/2022 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A RANDOMIZED, PARALLEL-ARM, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY WITH OPEN-LABEL EXTENSION TO ASSESS THE EFFICACY AND SAFETY OF VATIQUINONE FOR THE TREATMENT OF FRIEDREICH ATAXIA (MOVE-FA) No dispute reported 06/30/2026 960190805
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $35.00 01/01/2022 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Randomized Double-Blind Placebo-Controlled Parallel- Group Study to Evaluate the Efficacy and Safety of BHV-3241 in Subjects With Multiple System Atrophy (M-STAR Study) No dispute reported 06/30/2026 933375297
Principal investigator 2 Biohaven Pharmaceutical Holding Company Ltd. $35.00 01/01/2022 Non-covered Recipient Entity
COLUMBIA UNIVERSITY
A Randomized Double-Blind Placebo-Controlled Parallel- Group Study to Evaluate the Efficacy and Safety of BHV-3241 in Subjects With Multiple System Atrophy (M-STAR Study) No dispute reported 06/30/2026 933376679